D47.02 — Systemic mastocytosis
Is D47.02 billable?
Yes — D47.02 is billable for FY2027. D47.02 is a valid, billable ICD-10-CM code at the highest level of specificity in its branch. D47.02 may be submitted for encounters from October 1, 2026 through September 30, 2027.
D47.02 at a glance
| Code | D47.02 |
|---|---|
| Description | Systemic mastocytosis |
| Billable | Yes |
| Code set | ICD-10-CM FY2027 |
| Valid for encounters | October 1, 2026 – September 30, 2027 |
Which MS-DRGs does D47.02 group to?
D47.02 sits in MDC 17 and helps define the logic of 3 MS-DRGs (version 44, FY2027). Which one a stay actually groups to also depends on procedures and secondary diagnoses.
- 820Lymphoma and Leukemia with Major O.R. Procedures with MCCsurgical
- 821Lymphoma and Leukemia with Major O.R. Procedures with CCsurgical
- 822Lymphoma and Leukemia with Major O.R. Procedures without CC/MCCsurgical
As a secondary diagnosis, D47.02 is a complication or comorbidity (CC), which can move a stay into a higher-paying DRG.
How is D47.02 listed in the Alphabetic Index?
These are the routes through the Alphabetic Index that lead to D47.02. They show the wording a clinician may have documented, which often differs from the Tabular description.
- Disease, diseased › systemic tissue mast cell
- Mast cell › disease, systemic tissue
- Mastocytosis › indolent systemic
- Mastocytosis › isolated bone marrow
- Mastocytosis › systemic › with an associated hematological non-mast cell lineage disease
Excludes1 — never code together
The conditions below can never be reported together with D47.02 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.
Code also
Two codes may be needed to describe the condition fully. Whether D47.02 is sequenced first depends on the reason for the encounter.
- , if applicable, any associated hematological non-mast cell lineage disease, such as:
- acute myeloid leukemia (C92.6-, C92.A-)
- chronic myelomonocytic leukemia (C93.1-)
- essential thrombocytosis (D47.3)
- hypereosinophilic syndrome (D72.1)
- myelodysplastic syndrome (D46.9)
- myeloproliferative syndrome (D47.1)
- non-Hodgkin lymphoma (C82-C85)
- plasma cell myeloma (C90.0-)
- polycythemia vera (D45)
Inclusion terms
Alternative wording in documentation that is classified to D47.02.
- Indolent systemic mastocytosis
- Isolated bone marrow mastocytosis
- Smoldering systemic mastocytosis
- Systemic mastocytosis, with an associated hematological non-mast cell lineage disease (SM-AHNMD)
Excludes1 — never code together — inherited from D37-D48
The conditions below can never be reported together with D47.02 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.
- neoplasms of unspecified behavior (D49.-)
Excludes1 — never code together — inherited from D47.0
The conditions below can never be reported together with D47.02 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.
How long has D47.02 existed?
D47.02 first appears in FY2018 (FY2017 is not available, so it may have appeared then).
Derived from the official order files for FY2016–FY2026. FY2017 and FY2020 publish no order file, so those years are not covered.